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(UK) to € 77,854 (China) per quality adjusted life years (QALY) and € 37,361 per life 
years gained (LYG)(Europe and Canada). One French study showed an improvement 
in survival of 4 months between 2004 and 2012, with an ICER of € 54,355 per LYG, 
due to an increased use of temozolomide and bevacizumab. ConClusions: The 
literature on the cost of treatment and follow up of glioblastoma patients and on the 
cost-effectiveness of treatment modalities used in glioblastoma is scarce. Wide vari-
ations in cost are reported, probably reflecting the variation in health care systems.
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objeCtives: To characterise the economic burden of myelofibrosis and associated 
areas of unmet need. Methods: A systematic literature review was performed for 
world-wide cost-effectiveness, cost and resource studies published between January 
2004 and September 2014. Databases included MEDLINE, MEDLINE In-process, 
EconLit, EMBASE and the Cochrane Library, as well as HTA websites. Results: The 
search identified 261 cost-effectiveness and 231 cost and resource papers. Following 
two rounds of assessment, two and eight studies, respectively, were included. 
Bennett et al., 2013, reported a substantial rise in total costs from USD10,523 in the 
year prior to diagnosis to USD51,654 in the year after diagnosis. A lifetime model 
developed by El Ouagari et al., 2012, (based on COMFORT-II data) predicted lifetime 
costs of CAD494,859 and CAD421,755 for ruxolitinib and best available therapy (BAT), 
respectively. The model calculated high indirect costs due to employment absentee-
ism for patients taking ruxolitinib (CAD71,848) and BAT (CAD96,458), indicating high 
burden for patients and society. Bennett et al. reported that costs were 85% greater in 
patients with previous anaemia treatment, including transfusions. Vekeman et al., 
2015, reported that 18% of transfusion-dependant patients received iron chelation 
therapy, with significantly higher monthly pharmacy costs vs. those without (mean 
difference: $1,426, p= 0.004). El Ouagari et al. predicted lifetime transfusion costs of 
CAD18,299 for patients taking ruxolitinib and CAD13,456 for those on BAT, suggest-
ing that patients treated with ruxolitinib may experience worsening of anaemia. 
This is consistent with COMFORT-I data, which showed that transfusion-dependant 
ruxolitinib patients increased from 25% at baseline to 40% at Weeks 8-12 (Pardanani 
and Tefferi, 2014; not identified via this search). ConClusions: Myelofibrosis leads 
to significant direct costs for health systems and substantial absenteeism costs for 
patients. Despite the available treatments, patients with disease and treatment 
emergent cytopenias and transfusion dependency require additional medical man-
agement, further augmenting the economic burden.
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objeCtives: To estimate the life time CoD in metastatic colorectal cancer (mCRC) 
patients who have progressed after standard therapies, in Turkish setting. Methods: 
A panel consisting of experts held a meeting to discuss the disease management in 
mCRC. They reviewed the literature and discussed the local clinical practices. All cost 
components (anticancer medications, routine care including inpatient and outpatient 
costs and adverse event management) were evaluated. The clinical/economic param-
eters were entered as inputs of a cohort partition model mimicking the follow-up of 
patients till death. Mid-2015 local prices for medications and procedures were used as 
sources. Mid-2015 EUR currency rate (2.9274TL/EUR) was used. Results: Percentages 
of patients according to the pharmaceuticals for anticancer treatment were as follows: 
capecitabine 85%, bevacizumab 35%, 5-FU+bevacizumab 12.5%, Mod-FOLFIRINOX 7.5% 
and raltitreksed 1.5%. Other pharmacologic treatment included medications related 
with gastrointestinal symptoms (antacid, anti-diarrheal, anti-emetic), analgesics 
and opioids. Outpatient costs included oncologist visits, blood tests, imaging and 
palliative radiotherapy (in 5%). Adverse events evaluated included constitutional, 
skin, cardiac, pulmonary, gastrointestinal, blood/bone marrow, infectious, neuro-
logic and metabolic events. The components of life time CoD (2544EUR) were as fol-
lows: anticancer treatment (216EUR), other pharmaceuticals (95EUR), routine care 
(247EUR) (inpatient 120EUR + outpatients 127EUR) and adverse event management 
(5.5EUR). ConClusions: The most costly component of expenses in mCRC is anti-
cancer treatment followed by routine care costs. Especially off-label chemotherapy 
agents are constituted significant part of this routine care costs.
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objeCtives: To summarize the existing literature regarding the medical cost and 
cost-effectiveness associated with treatment and follow-up of pancreatic can-
cer. Methods: PubMed was used as search engine to retrieve publications in 
Medline, using the search terms “pancreatic cancer” AND “cost” with a publica-
tion date filter (from January 1st 2000 up to September 1st2014) and language filter 
(English). This search yielded 416 results of which 48 were relevant for this review. 
Cost were recalculated in Euros (€ ) using the June 5 2015 currency rate of $1 = € 0.8914, 
CA$1 = € 0.7131 and £1 = € 1.3667. Results: The medical cost from diagnosis to death 
of one or more stages of pancreatic cancer were reported in 8 studies conducted in 
USA (n= 3), Sweden (n= 3), Germany (n= 1) and Japan (n= 1). Four studies included 
p< 0.001; second-line treatment: coefficient 0.377, p= 0.019), pulmonary infection 
(coefficient 0.780, p< 0.001), and suppressed bone marrow function (coefficient 0.352, 
p= 0.047) were significantly associated with increased direct medical costs and urban 
resident insurance (coefficient -0.410, p< 0.001) was significantly associated with less 
direct medical costs. ConClusions: The direct medical costs associated with MM 
in publically insured Chinese patients varied substantially by treatment settings. 
Except treatment settings, complications, and comorbidities, the social economic sta-
tus associated with insurance type and residence city size have a substantial impact 
on public health resource utilization in Chinese patients with MM.
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objeCtives: Breast cancer screening has resulted in increased diagnosis of ductal 
carcinoma in situ (DCIS). Compared with other breast cancers, little is known about 
the cost of illness or quality of life burden associated with DCIS. Methods: A struc-
tured literature search strategy was developed for identifying DCIS cost and QOL data 
in three publication databases (PubMed, EMBASE, and the Cochrane Library). Primary 
and secondary search criteria were “Carcinoma, Intraductal, Noninfiltrating” or “DCIS” 
and “Quality of life” or “Costs” or “Resource use”, respectively. Publications for review 
were restricted to those published between 2004 and 2014 inclusive. Abstract screen-
ing was performed by a single reviewer, with included results checked for protocol 
alignment by two further reviewers. Results: In total, 585 articles were identified 
for review, of which 55 were duplicates between databases. Following abstract review, 
111 articles were retained for analysis. The majority of excluded articles were not 
specific to DCIS or did not report cost or QOL data. DCIS does not directly affect QOL. 
Anxiety caused by DCIS diagnosis is a key decrement to QOL, although its impact can 
be transient. Longer term impacts on body image and role limitation were apparent 
following surgical intervention. Evidence of QOL detriments due to DCIS treatment 
were identified. Use of post-surgical radiotherapy is increasing, and patients receiving 
lumpectomy plus radiotherapy had significantly lower ‘mental health’ (74.0 vs. 77.4) 
and ‘vitality’ (59.3 vs. 63.5) QOL than controls. There is little data on the cost burden 
of DCIS. Individual cost items were identified, with radiotherapy estimated at USD 
10,700 to 34,900. ConClusions: Anxiety about tumour recurrence and body image 
and treatment side effects are the major factors influencing patient QOL in DCIS. 
Adverse events and costs associated with DCIS treatments makes the choice of treat-
ment pathway important for both patients and healthcare providers.
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objeCtives: Cervical cancer, caused by oncogenic Human Papillomavirus (HPV) 
types, is in Croatia the tenth most common cancer in women and accounted for 106 
women deaths in 2012. The aim of this study was to evaluate the costs associated 
with the diagnostic and treatment of cervical cancer and cervical intraepithelial 
neoplasia in Croatia in 2012. Methods: Publicly available data on the costs related 
to cervical cancer and cervical intraepithelial neoplasia diagnostic and treatment 
were collected. The main sources for the number of cases were the Croatian Institute 
of Public Health Yearbook for 2012 and Croatian Cancer Registry data. For the unit 
cost, the list of Diagnosis-Related Groups codes was used. When country-specific 
information was unavailable, reference to international data was used. Total cost 
was calculated by multiplying the number of cases with unit cost. Only direct medi-
cal costs were taken into consideration, using governmental perspective. Results: 
In 2012, cervical cancer and cervical intraepithelial neoplasia amounted to a total 
cost of € 5,418,790.70. Papanicolaou (Pap) smear tests represent the major source of 
expenditure with a total cost of € 2,367,686.92. A total of 374,484 Pap smear tests were 
carried on in 2012, from which 7.3% were pathological. ConClusions: Cervical 
cancer and cervical intraepithelial neoplasia caused by high risk oncogenic HPV-
types represent an important health and economic burden in Croatia. The results 
of this analysis may be useful to assess the potential reduction in cost associated 
with HPV-related diseases if additional prevention strategies were implemented.
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objeCtives: To summarize the existing literature regarding the medical cost associ-
ated with treatment and follow-up of glioblastoma. Methods: PubMed was used 
as search engine to retrieve publications in Medline using the search terms “(glio-
blastoma) AND (cost)” with a publication date filter (from January 1st 2000 up to 
September 1st2014) and language filter (English). This search yielded 107 publica-
tions of which 14 were relevant for this review. Costs were recalculated in Euros 
(€ ) using the June 5 2015 currency rate of $1 = € 0.8914, CA$1 = € 0.7131 and 1£ = 
€ 1.3667. Results: Two studies calculated the average total medical cost of glioblas-
toma treatment including direct hospital centered costs from diagnosis to death 
and one study included healthcare payer perspective cost from diagnosis to two 
years of follow-up. The cost ranged between € 12,229 - € 43,894 (median: € 39,000). Two 
studies calculated the average cost of the combination of surgery and chemoradio-
therapy which varied from € 16,007 per patient in Canada to € 41,744 per patient in 
Switzerland. The addition of temozolomide to radiotherapy prolongs survival and 
improves quality of life. The incremental cost-effectiveness ratio (ICER) of temozo-
lomide plus radiotherapy as compared to radiotherapy alone ranged from € 49,054 
